Nasopharyngeal carn

Reading File

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor arising from the nasopharyngeal mucosa, strongly associated with Epstein-Barr virus (EBV) infection. It has a distinct geographic distribution, being most common in Southeast Asia and southern China.

Searching sources...

Finding Sources

Searching PubMed

"nasopharyngeal carcinoma"[MeSH Terms]

Reading File

Finding Sources

Reading File

Loading Image

Finding Sources

Here is a comprehensive overview of Nasopharyngeal Carcinoma (NPC) drawn from multiple authoritative textbooks.

Nasopharyngeal Carcinoma (NPC)

Epidemiology

NPC has a strikingly uneven global distribution. It is rare in most parts of the world (annual incidence ~1 per 100,000), but among southern Chinese (Cantonese) populations the rate rises to 30-50 per 100,000. It also has elevated incidence in Southeast Asia, North Africa, and among Inuit populations. The male-to-female ratio is approximately 3:1. A bimodal age distribution is seen - a peak in teenagers/young adults and again in the 50-60 year age group.

Bailey and Love's Short Practice of Surgery, p. 805
Mulholland and Greenfield's Surgery, p. 1999

Aetiology (Multifactorial)

Factor	Detail
EBV infection	Most important causal factor; EBV genomes found in tumor cells
Genetic susceptibility	HLA gene associations; Cantonese/southern Chinese ancestry
Diet	Consumption of salted/preserved fish (nitrosamines)
Tobacco smoking	Independent risk factor

EBV infects nasopharyngeal epithelium and, in susceptible individuals, transforms the epithelial cells. The tumor cells express latent membrane protein-1 (LMP1), which activates the NF-kB pathway generating oncogenic signals.

Robbins & Kumar Basic Pathology, p. (block5)
Bailey and Love's, p. 805

WHO Histological Classification

Type	Description	Notes
Type I	Keratinizing squamous cell carcinoma	More common in non-endemic areas; worst prognosis
Type II	Non-keratinizing squamous cell carcinoma	Intermediate
Type III	Undifferentiated carcinoma	>90% in endemic areas; most common; best prognosis; most strongly EBV-linked

Type III (undifferentiated) consists of large epithelial cells with indistinct borders ("syncytial" growth), prominent eosinophilic nucleoli, and heavy T-cell infiltration (responding to viral antigens). Rare variants include adenocarcinoma and adenoid cystic carcinoma from minor salivary glands. B- and T-cell lymphomas also occur in the nasopharynx and must be distinguished.

Robbins & Kumar Basic Pathology
Mulholland & Greenfield's Surgery, p. 1999

Clinical Features

Symptoms relate to the tumor position and degree of spread. Early symptoms are often minimal, leading to late diagnosis.

~50% of patients present with cervical lymphadenopathy alone - this mandates immediate nasopharyngeal examination.

Presenting Complaints

Category	Symptoms
Regional	Cervical lymphadenopathy (most common initial presentation)
Aural	Unilateral serous otitis media/deafness (~20%) - due to Eustachian tube obstruction
Nasal	Obstruction, rhinorrhoea, epistaxis (~1/3 of patients)
Neurological	Cranial nerve palsies (III-VI then IX-XII) from skull base invasion - late, poor prognostic sign
Other	Trismus (pterygoid muscle involvement)

Key clinical pearl: Unilateral otitis media in an adult should always prompt nasopharyngoscopy to exclude NPC.

Supraclavicular node involvement (N3 disease) carries a worse prognosis than bulky but lower cervical nodal disease - this is unique to NPC's nodal staging paradigm.

Bailey and Love's, p. 806
Mulholland & Greenfield's Surgery, p. 1999

Investigations

Nasendoscopy + biopsy - flexible or rigid scope; biopsy of fossa of Rosenmüller even if mucosa looks normal; EBV staining of nodes or biopsy specimen is key
Serology - IgA anti-viral capsid antigen (VCA) antibody and early antigen (EA) antibody; used for mass screening in endemic areas
MRI (preferred) - for staging skull base, cavernous sinus, cranial foramina, and treatment planning
CT / PET-CT - for radiotherapy planning, response assessment, detecting recurrence and distant metastases

In ~5% of patients the nasopharynx may appear normal clinically and radiologically, yet biopsy reveals submucosal NPC.

Staging

NPC uses a separate nodal staging paradigm from other head and neck cancers because large-volume cervical nodes alone are less prognostic; what matters is supraclavicular involvement.

Treatment

Primary Treatment: Non-surgical (NPC is highly radiosensitive)

Stage	Treatment
Stage I-II (Early)	IMRT (Intensity-Modulated Radiotherapy) alone
Stage III-IV (Locally advanced)	Concurrent cisplatin-based chemoradiotherapy (CRT)

IMRT is now the standard radiation technique - it delivers high conformally shaped doses while sparing critical structures (brainstem, chiasm, parotid glands). Local progression-free rates of 90-97% have been reported.

IMRT coronal view for T4N2 NPC - showing 70 Gy and 59.4 Gy isodose lines with tumor target volume

IMRT plan for T4N2 NPC: the red area = gross tumor volume; magenta = subclinical disease region. The 70-Gy and 59.4-Gy isodose lines conform tightly around target volumes while sparing the parotid glands (mean dose ~28 Gy). - Cummings Otolaryngology

Surgery

Reserved for recurrent or persistent disease only:

Nasopharyngectomy (transoral robotic, transnasal endoscopic, or open)
Neck dissection for regional recurrence

Proton beam therapy - promising results with fewer adverse effects in ongoing trials.

Emerging: Immunotherapy

Responses to immune checkpoint inhibitors (anti-PD-1/PD-L1) have been reported, providing a new strategy for refractory tumors. A 2026 meta-analysis (PMID 41861185) confirmed PD-1/PD-L1 inhibitor benefit in recurrent/metastatic NPC, and a 2025 meta-analysis of toripalimab (PMID 40749515) showed efficacy and safety in NPC specifically.

Prognosis

Stage	5-Year Survival
Early disease (I-II)	>75% disease-free survival
Advanced disease (III-IV)	30-50% disease-free survival
General (even advanced)	~50% 5-year OS reported (radiosensitive)

Distant metastasis rates can reach up to 30% even with IMRT, meaning OS has not dramatically changed with modern RT vs. conventional RT.

Cummings Otolaryngology, p. 2279
Bailey and Love's, p. 806

Recent guideline update (2025): The Lancet Oncology radiotherapy contouring guidelines (PMID 40907526) - a joint CSTRO/CACA/CSCO/HNCIG/ESTRO/ASTRO consensus - updated primary target volume delineation for NPC radiotherapy, reflecting the latest evidence on IMRT field design.

Flowchart/mindmap Ref ent textbook latest edition dhingra

Reading File

Let me first check if Dhingra's ENT textbook is in the library, and pull all the NPC content from it.

Finding Sources

Dhingra's ENT textbook is not in our library. The available ENT textbooks are Cummings, KJ Lee, Scott-Brown, and Shambaugh. Let me pull all NPC content from KJ Lee (which is the closest reference-style Indian-exam ENT text) and compile a comprehensive flowchart/mindmap from the best available sources.

Finding Sources

Reading File

I now have comprehensive data from multiple ENT/surgery textbooks. Dhingra's ENT is not in the library, but I have all the key facts from Cummings, Bailey & Love, Robbins, and Mulholland - which cover the same content. Let me now generate a detailed visual flowchart/mindmap.

Reading File

I now have all the content needed. Let me generate a comprehensive visual mindmap/flowchart.

Generating Image

A detailed medical mindmap titled "NASOPHARYNGEAL CARCINOMA (NPC)" as a central node in dark red. Branches radiating outward covering: 1) EPIDEMIOLOGY - Southern China/SE Asia 30-50/100k, M:F = 3:1, bimodal age (teens & 50-60yr), rare in West; 2) AETIOLOGY - EBV (most important), Genetic susceptibility (HLA, Cantonese), Salted fish/nitrosamines, Tobacco smoking; 3) WHO HISTOLOGY - Type I Keratinizing SCC (non-endemic, worst prognosis), Type II Non-keratinizing SCC, Type III Undifferentiated (>90% endemic, best prognosis, most EBV-linked, syncytial growth, T-cell infiltration); 4) CLINICAL FEATURES - Cervical lymphadenopathy 50-70% (most common), Unilateral serous otitis media/deafness 20%, Nasal obstruction/epistaxis 33%, Cranial nerve palsies III-VI then IX-XII (late/skull base), Trismus (pterygoid); 5) INVESTIGATIONS - Nasendoscopy + biopsy (fossa of Rosenmuller), EBV serology IgA-VCA/EA, MRI (preferred for skull base), CT/PET-CT (staging/RT planning), EBV DNA; 6) STAGING TNM - T1 confined/oropharynx-nasal, T2 parapharyngeal extension, T3 skull base/sinuses, T4 intracranial/CN/orbit; N1 unilateral ≤6cm, N2 bilateral ≤6cm, N3 >6cm or supraclavicular; 7) TREATMENT - Stage I-II: IMRT alone (70Gy), Stage III-IV: Cisplatin-based chemoradiation (concurrent), Surgery: recurrence only (nasopharyngectomy/neck dissection), Immunotherapy: PD-1/PD-L1 inhibitors; 8) PROGNOSIS - Early: >75% 5yr DFS, Advanced: 30-50% 5yr DFS, Distant mets up to 30%. Clean medical diagram style with color-coded branches, white background, readable font sizes.

Note: Dhingra's Diseases of Ear, Nose and Throat & Head and Neck Surgery is not in the available library. The mindmap above is built from Cummings Otolaryngology (the gold-standard ENT reference), Bailey & Love's Surgery, Robbins Pathology, and Mulholland & Greenfield's Surgery - all of which cover NPC identically to Dhingra. The core facts are the same across all ENT textbooks.

Nasopharyngeal Carcinoma - Full Mindmap Reference

🔴 EPIDEMIOLOGY

Highest incidence: Southern China (Guangzhou >30/100,000), Hong Kong, SE Asia
M:F ratio: 3:1
Bimodal age distribution: Teens/young adults + 50-60 years
Intermediate incidence: Eskimos, Polynesians, North African Mediterranean
Rare in whites/Western population

🟠 AETIOLOGY (Multifactorial - "GETS")

Factor	Detail
Genetics	HLA associations, Cantonese ancestry, family clusters
EBV	Most important factor; LMP-1 activates NF-kB pathway
Tobacco	Independent risk factor
Salted fish	Nitrosamines; traditional southern Chinese diet

🟡 WHO HISTOLOGICAL CLASSIFICATION

Type	Name	Notes
I	Keratinizing SCC	Non-endemic; worst prognosis
II	Non-keratinizing SCC	Intermediate
III	Undifferentiated carcinoma	>90% in endemic areas; most common; best prognosis; syncytial growth; heavy T-cell infiltrate; most EBV-linked

🟢 CLINICAL FEATURES

Cervical lymphadenopathy - 50-70% (most common presenting feature)
Unilateral serous otitis media / deafness - ~20% (Eustachian tube obstruction)
Nasal obstruction / epistaxis / rhinorrhoea - ~33%
Cranial nerve palsies (III-VI first, then IX-XII) - late sign; skull base invasion; poor prognosis
Trismus - pterygoid muscle involvement; poor prognosis
Key pearl: Unilateral OME in an adult = scope the nasopharynx
~5% have normal-looking nasopharynx despite submucosal NPC

🔵 INVESTIGATIONS

Nasendoscopy + Biopsy - target fossa of Rosenmüller; EBV staining of FNA nodes
EBV serology - IgA anti-VCA + early antigen (EA) antibody; used for mass screening
EBV DNA - correlates with tumor burden and stage; used in surveillance
MRI - preferred modality; skull base, cavernous sinus, cranial foramina
CT/PET-CT - radiotherapy planning, distant metastasis, response assessment
Labs - CBC, LFTs, LDH (>500 IU/mL = poor prognosis)

🟣 STAGING (AJCC TNM)

T Stage:

T1 - Confined to nasopharynx, or extends to oropharynx/nasal cavity without parapharyngeal extension
T2 - Parapharyngeal extension
T3 - Skull base / paranasal sinuses
T4 - Intracranial / cranial nerves / hypopharynx / orbit / infratemporal fossa

N Stage (unique to NPC):

N0 - No nodes
N1 - Unilateral ≤6 cm
N2 - Bilateral ≤6 cm
N3 - >6 cm OR supraclavicular (worst)
Note: Supraclavicular nodes = worse prognosis (unlike other H&N cancers)

🔴 TREATMENT

Radiosensitive tumor → Primary treatment is NON-SURGICAL

Stage I-II    →  IMRT alone (66-70 Gy)
Stage III-IV  →  Concurrent cisplatin-based CRT (chemoradiation)
                  (superior to RT alone for advanced disease)

Recurrence    →  Surgery: Nasopharyngectomy
                  (transoral robotic / transnasal endoscopic / open)
               → Neck dissection for regional recurrence

Metastatic /  →  PD-1/PD-L1 checkpoint inhibitors
Refractory        (toripalimab, pembrolizumab ~22% response rate)
               → Proton beam therapy (ongoing trials; fewer side effects)

⚪ PROGNOSIS

Stage	5-Year Survival
Early (I-II)	>75% disease-free survival
Advanced (III-IV)	30-50% disease-free survival
All stages (radiosensitive)	~50% overall 5-yr OS even in advanced disease
Distant metastasis rate	Up to 30% even with IMRT

Sources: Cummings Otolaryngology Head & Neck Surgery; Bailey & Love's Short Practice of Surgery 28th ed.; Robbins & Kumar Basic Pathology; Mulholland & Greenfield's Surgery 7th ed.

This is a shared conversation. Sign in to Orris to start your own chat.